Literature DB >> 16033949

Functional characterization of three naturally occurring single nucleotide polymorphisms in the CES2 gene encoding carboxylesterase 2 (HCE-2).

Takashi Kubo1, Su-Ryang Kim, Kimie Sai, Yoshiro Saito, Toshiharu Nakajima, Kenji Matsumoto, Hirohisa Saito, Kuniaki Shirao, Noboru Yamamoto, Hironobu Minami, Atsushi Ohtsu, Teruhiko Yoshida, Nagahiro Saijo, Yasuo Ohno, Shogo Ozawa, Jun-Ichi Sawada.   

Abstract

Twelve single nucleotide polymorphisms (SNPs) in the human CES2 gene, which encodes a carboxylesterase, hCE-2 [human carboxylesterase 2 (EC 3.1.1.1)], have been reported in the Japanese. In this report, we have examined functional alterations of three SNPs, a nonsynonymous SNP (100C>T, R34W), an SNP at the splice acceptor site in intron 8 (IVS8-2A>G), and one newly discovered nonsynonymous SNP (424G>A, V142M). For the two nonsynonymous SNPs, the corresponding variant cDNAs were expressed in COS-1 cells. Both the R34W and V142M variants showed little esterase activities toward the anticancer agent irinotecan and two typical carboxylesterase substrates, p-nitrophenol acetate and 4-methylumbelliferyl acetate, although increased levels of cDNA-mediated protein expression were observed by Western blotting as compared with the wild type. To investigate a possible splicing aberration in IVS8-2A>G, an in vitro splicing assay was utilized and transcripts derived from CES2 gene fragments of the wild type and IVS8-2A>G were compared. Sequence analysis of the cloned transcripts revealed that IVS8-2A>G yielded mostly aberrantly spliced transcripts, including a deleted exon or a 32-bp deletion proximal to the 5' end of exon 9, which resulted in truncated hCE-2 proteins. These results suggested that 100C>T (R34W), 424G>A (V142M), and IVS8-2A>G are functionally deficient SNPs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16033949     DOI: 10.1124/dmd.105.005587

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  11 in total

Review 1.  Regulations of Xenobiotics and Endobiotics on Carboxylesterases: A Comprehensive Review.

Authors:  Yanjiao Xu; Chengliang Zhang; Wenxi He; Dong Liu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-08       Impact factor: 2.441

Review 2.  Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Authors:  Mariusz Panczyk
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

3.  Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients.

Authors:  Kimie Sai; Yoshiro Saito; Naoko Tatewaki; Masakiyo Hosokawa; Nahoko Kaniwa; Tomoko Nishimaki-Mogami; Mikihiko Naito; Jun-Ichi Sawada; Kuniaki Shirao; Tetsuya Hamaguchi; Noboru Yamamoto; Hideo Kunitoh; Tomohide Tamura; Yasuhide Yamada; Yuichiro Ohe; Teruhiko Yoshida; Hironobu Minami; Atsushi Ohtsu; Yasuhiro Matsumura; Nagahiro Saijo; Haruhiro Okuda
Journal:  Br J Clin Pharmacol       Date:  2010-08       Impact factor: 4.335

Review 4.  The role of human carboxylesterases in drug metabolism: have we overlooked their importance?

Authors:  S Casey Laizure; Vanessa Herring; Zheyi Hu; Kevin Witbrodt; Robert B Parker
Journal:  Pharmacotherapy       Date:  2013-02       Impact factor: 4.705

Review 5.  Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer.

Authors:  Ken-ichi Fujita; Yutaro Kubota; Hiroo Ishida; Yasutsuna Sasaki
Journal:  World J Gastroenterol       Date:  2015-11-21       Impact factor: 5.742

Review 6.  Pharmacogenomics, biomarker network, and allele frequencies in colorectal cancer.

Authors:  Andrés López-Cortés; César Paz-Y-Miño; Santiago Guerrero; Gabriela Jaramillo-Koupermann; Ángela León Cáceres; Dámaris P Intriago-Baldeón; Jennyfer M García-Cárdenas; Patricia Guevara-Ramírez; Isaac Armendáriz-Castillo; Paola E Leone; Luis Abel Quiñones; Juan Pablo Cayún; Néstor W Soria
Journal:  Pharmacogenomics J       Date:  2019-10-15       Impact factor: 3.550

7.  Interaction between polymorphisms in aspirin metabolic pathways, regular aspirin use and colorectal cancer risk: A case-control study in unselected white European populations.

Authors:  Harsh Sheth; Emma Northwood; Cornelia M Ulrich; Dominique Scherer; Faye Elliott; Jennifer H Barrett; David Forman; C Roland Wolf; Gillian Smith; Michael S Jackson; Mauro Santibanez-Koref; Robert Haile; Graham Casey; Mark Jenkins; Aung Ko Win; John L Hopper; Loic Le Marchand; Noralane M Lindor; Stephen N Thibodeau; John D Potter; John Burn; D Timothy Bishop
Journal:  PLoS One       Date:  2018-02-09       Impact factor: 3.240

8.  Predicting the Effects of CYP2C19 and Carboxylesterases on Vicagrel, a Novel P2Y12 Antagonist, by Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Approach.

Authors:  Shuaibing Liu; Ziteng Wang; Xin Tian; Weimin Cai
Journal:  Front Pharmacol       Date:  2020-12-08       Impact factor: 5.810

Review 9.  Carboxylesterases in lipid metabolism: from mouse to human.

Authors:  Jihong Lian; Randal Nelson; Richard Lehner
Journal:  Protein Cell       Date:  2017-07-04       Impact factor: 14.870

Review 10.  Human carboxylesterases: a comprehensive review.

Authors:  Dandan Wang; Liwei Zou; Qiang Jin; Jie Hou; Guangbo Ge; Ling Yang
Journal:  Acta Pharm Sin B       Date:  2018-06-25       Impact factor: 11.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.